Kairos Pharma Ltd. (NYSE American: KAPA) announced its participation in the DealFlow Discovery Conference scheduled for January 28–29, 2026, at the Borgata Hotel, Casino & Spa in Atlantic City, New Jersey. The company's Chief Scientific Officer, Neil Bhowmick, will deliver a presentation and conduct one-on-one meetings with investors during the event. This participation comes as Kairos continues to advance its clinical-stage oncology programs, positioning the company at a critical juncture for investor engagement and scientific validation.
The importance of this announcement lies in the broader context of Kairos Pharma's research focus on overcoming drug resistance and immune suppression in cancer. The company utilizes structural biology to develop therapeutics that address significant unmet medical needs in oncology. Kairos's lead candidate, ENV-105, is an antibody targeting CD105, a protein identified as a key driver of resistance and disease relapse in response to standard cancer therapies. By targeting CD105, ENV-105 aims to reverse drug resistance and restore the effectiveness of standard treatments across multiple cancer types.
Currently, ENV-105 is in a Phase 2 clinical trial for castrate-resistant prostate cancer and a Phase 1 trial for non-small cell lung cancer. It is crucial to note that, as of the press release date, ENV-105 has not been approved as safe or effective by the United States Food and Drug Administration or any comparable foreign regulator. The clinical progress of ENV-105 underscores the potential impact on patients facing cancers where resistance to existing therapies remains a major challenge, potentially improving treatment outcomes and survival rates.
The DealFlow Discovery Conference provides a platform for Kairos to showcase its scientific advancements to a targeted audience of investors and industry stakeholders. Such events are instrumental for small-cap and mid-cap companies like Kairos in securing funding, partnerships, and visibility necessary to advance clinical trials. The conference is organized through platforms like TinyGems, a specialized communications platform within the Dynamic Brand Portfolio at IBN, which focuses on innovative companies with growth potential. More information about Kairos Pharma's updates is available in the company's newsroom at https://ibn.fm/KAPA.
For investors and the oncology community, Kairos's participation highlights the ongoing innovation in cancer therapeutics, particularly in addressing drug resistance—a persistent barrier in cancer treatment. The implications extend beyond immediate financial interests to potential advancements in patient care, as successful development of ENV-105 could offer new options for cancers with limited effective treatments. As the conference approaches, stakeholders will be watching for updates on clinical trial progress and strategic developments from Kairos Pharma.
